- @bcrc.beTél: 065/40 34 34 1 New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING NEW GENERATION BIOMIMETIC AND CUSTOMIZED

- www.bcrc.be [email protected] Tél: 065/40 34 34 1

New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING

NEW GENERATION BIOMIMETIC AND CUSTOMIZED IMPLANTS

FOR BONE ENGINEERING

Brussels, 9th March 2015

COST Action – MP 1301 – http://www.cost-newgen.org

Chair : Dr Francis Cambier




What context ?

With a predicted ageing population and increasing expectations regarding quality of life in old age, there is an ever increasing demand for procedures such as total hip replacements, bone reconstructions, and spinal fusions, resulting from conditions such as joint cartilage degeneration and osteoporosis.

Due to the gap between academic R&D and commercial production, and between materials scientists and clinicians, medical application of these new materials will never be possible unless companies and medics are involved in the development.

This COST Action, NEWGEN, aims at creating the seed for the European research and industry collaboration, combining basic knowledge from academic laboratories, R&D centers, medical units from hospitals, and a significant number of companies





Some figures

One third of the population is more than 60 years old in 2010 600.000 hip replacements in Europe /year 150.000 invasive spinal fusions in Europe /year More than 4.000.000 operations involving bone grafting or bone substitutes

performed around the world / year

Orthopedic biomaterials market : ~ $8 billions (grow rate 5%) US: 42 %, Europe: 31 %




The need of cooperation

DesignBiomaterials preparation

Processing

Characterisations Functionalization

In vitro / In vivo testings

Me

dica

l asse

ssme

nt

Fabrication

Strong interactions between Strong interactions between ::

R&D

Hospital units

Producers

Surgical operation




Lack of communications between R&D, Hospital units and Industry Unique opportunity to link European researchers to industries and end-users




– Establish a structured coordination, helping in the development of the right products.

– R&D increasing performance– Increase of competitiveness of European companies

Objectives, benefits, impacts

Concrete achievements– Multi-partners projects, mainly on new bioactive and customized

bone implants, incorporating every aspect of the whole value chain (including H2020 projects)

– Attraction of an Asian company to Europe– Dissemination (1 collective book, papers, Web site)



Consortium of partners– 29 COST countries + 3 non-COST countries (USA, Canada, Australia)– 141 partners

– 50% of the consortium members are companies, surgeons/medical units and research centers




How it works

COST Office

Management committee

WG 1 WG 3 WG 4WG 2

• Chair/Vice-chair• 4 WG Leaders• At least 1 by COST country• 1 by non-COST participant

Members

• 1 WG Leader – 1 vice leader• Transversal activities (web page feeding, events organisation, communication, STSMs…)• Each WG will consist of partners from academic institutes, industries and medical units

Core group

• Chair, VC, WG leaders• GH• STSM, Dissemination, Web




The tools Core group meetings WG meetings Scientific workshops MC meetings (to approve the suggestions)

STSM – selection is difficult: 1st quality, ECI , inclusiveness policy countries, gender balance, etc.

Summer schools

Dissemination – grants, book, papers, etc. http://www.cost-newgen.org




Is it easy ? How to get the support of COST:

– Pre-proposal (4 pages, web) 30rd Sept 2012 2 experts eligible (10th Oct 2012) ok for a full proposal (end Nov 2012)

– Proposal (40 pages) end Jan 2013 experts– Selection to present (orally) DC Hearing in Brussels (40 people, mid March 2013) – Decision of DC (9th April 2013) administrative details to be completed– Decision by Cost Office and CSO (end of May 2013) beginning of signature of MoU by the

countries– Kick Off Meeting 2nd Oct 2013 (starting date)

The language:– Everything is in the Vademecum (including a 2 pages lexicon)– Examples : WG, STSM, LOS, ECI (was ESR), GH, MC, AO, SO, KOM, CNC, SC, EB, (CSO, DC ?), etc.

The role of the grant holder:– Follow the rules (Vademecum) while scientists do not understand (or are not willing to do that)

A difficulty and advantage:– loss of control of the players (members of MC) – but it is a part of the interest opening to

new countries, etc.




Thank you for your attention

Conclusion: A very nice experience

Documents

- @bcrc.beTél: 065/40 34 34 1 New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING NEW GENERATION BIOMIMETIC AND CUSTOMIZED